ArticleJournal of gastrointestinal oncology2026
Transarterial embolization combined with octreotide long-acting release in treating rectal neuroendocrine tumor liver metastases: a single-institutional experience.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver metastasis is a critical factor of mortality and morbidity in patients with neuroendocrine tumor, and effective management strategies remain a clinical challenge. The treatment regimen of transarterial embolization (TAE) combined with octreotide long-acting release (LAR) for the subgroup of rectal neuroendocrine tumor liver metastases (NETLMs) have not been specially investigated. This study aims to evaluate the efficacy and factors of hepatic progression-free survival (HPFS) and treatment response in patients with rectal NETLMs receiving TAE plus octreotide LAR therapy. Methods: This was a retrospective study, which enrolled 84 patients with rectal NETLMs receiving the combination therapy of TAE and octreotide LAR between January 2022 and December 2024. Patients' data were reviewed to evaluate prognostic factors of HPFS and treatment response by the univariate and multivariate Cox proportional hazards models and logistic regression models. Results: The median HPFS was 11.1 months. Partial response (PR) in 71 patients (84.5%), stable disease (SD) in 9 patients (10.7%), and progressive disease (PD) in 4 patients (4.8%) were observed. The objective response rate (ORR) was 84.5% in the cohort. In the multivariate Cox regression model, hepatic tumor burden (HTB) ≤25% [hazard ratio (HR) =4.188, P=0.02] was an independent risk factor for HPFS. In the multivariate logistic regression model, tumor border [odds ratio (OR) =0.069, P=0.01] was a positive prognostic factor of treatment response, while Conclusions: The therapeutic strategy of TAE combined with octreotide LAR were effective in patients with rectal NETLMs, especially in those with HTB ≤25%. Selected patients with Ki-67 ≤10%, negative
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.